☆ 4.6 Editorial Material

MELANOMA Smart therapeutic strategies in immuno-oncology

NATURE REVIEWS CLINICAL ONCOLOGY (2014)

期刊

NATURE REVIEWS CLINICAL ONCOLOGY

卷 11, 期 4, 页码 181-182

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/nrclinonc.2014.36

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

摘要

For cancer therapies to succeed, induction of an anticancer immune response is required. Immuno-oncology approaches are shaping the treatment landscape for patients with advanced-stage melanoma and other solid tumours. These new approaches may enhance immune system activity to improve outcomes, including the potential to achieve long-term survival benefits in many patients.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Pharmacology & Pharmacy

Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma

Yukari Nagao, Akira Yokoi, Kosuke Yoshida, Mai Sugiyama, Eri Watanabe, Kae Nakamura, Masami Kitagawa, Eri Asano-Inami, Yoshihiro Koya, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Tomoyasu Kato, Yusuke Yamamoto, Hiroaki Kajiyama

Summary: This study aimed to identify novel targets for uterine leiomyosarcoma (ULMS) through a three-step screening process using a chemical library. The candidates proscillaridin A and lanatoside C showed superior antitumor effects in mouse models. The downregulation of uncoupling protein 2 (UCP2) induced reactive oxygen species (ROS) and suppressed ULMS cell growth, making it a potential therapeutic target.

PHARMACOLOGICAL RESEARCH (2023)

添加到收藏夹

Review Dermatology

Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma

Inger Z. M. Kreuger, Roderick C. Slieker, Tim van Groningen, Remco van Doorn

Summary: Loss of CDKN2A is a common occurrence in melanoma progression and targeting this loss can significantly improve treatment outcomes. Various therapeutic strategies, such as CDK4/6 inhibition, cell cycle dysregulation, metabolic rewiring, epigenetic restoration, co-deleted gene targeting, and modulation of immune responses, have been explored in the context of CDKN2A loss.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

添加到收藏夹

Review Oncology

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches

M. James Lonie, P. Andrew Barbour, Riccardo Dolcetti

Summary: OAC incidence is rising globally, but current treatment regimens have limited success, highlighting the need for improved immunotherapeutic strategies. Understanding the immune responses to OAC is essential for enhancing therapeutic approaches and potentially improving patient outcomes.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Review Immunology

Leveraging NKG2D Ligands in Immuno-Oncology

Mercedes Beatriz Fuertes, Carolina Ines Domaica, Norberto Walter Zwirner

Summary: Immune checkpoint inhibitors have revolutionized immuno-oncology by achieving durable immune control of cancer, however, tumor immune evasion mechanisms pose a challenge for treatment development. Combination therapies targeting NK cell-activating receptors like NKG2D are emerging as frontrunners in immuno-oncology, with strategies to boost MICA/B expression and inhibit their shedding being proposed for enhancing antitumor immune responses.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Salivary gland cancers in elderly patients: challenges and therapeutic strategies

Elena Colombo, Charlotte Van Lierde, Alexandra Zlate, Alexandra Jensen, Gemma Gatta, Fabio Didone, Lisa F. Licitra, Vincent Gregoire, Vander Vander Poorten, Laura D. Locati

Summary: This article discusses the most common histological diagnoses of salivary gland carcinomas in the elderly population and the corresponding survival outcomes. It also reviews the current therapeutic strategies for locoregionally advanced and metastatic disease, considering the recent advances in precision oncology. The collaboration between the Multidisciplinary Tumor Board and the Geriatrician aims to determine the most appropriate treatment pathway for each elderly patient, focusing on overall functionality rather than chronological age.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Oxidative Stress in Melanoma: Beneficial Antioxidant and Pro-Oxidant Therapeutic Strategies

Alyssa L. Becker, Arup K. Indra

Summary: Cutaneous melanoma is a deadly form of skin cancer, and despite advancements in therapies, tumor resistance remains a challenge. Oxidative stress plays a paradoxical role in melanoma, promoting tumor initiation but inhibiting growth and metastasis. Manipulating the antioxidant system can enhance efficacy and survival, with antioxidant agents for chemoprevention and pro-oxidant agents for treatment.

CANCERS (2023)

添加到收藏夹

Review Immunology

Insights into immuno-oncology drug development landscape with focus on bone metastasis

Tiina E. Kahkonen, Jussi M. Halleen, Gary MacRitchie, Ronnie M. Andersson, Jenni Bernoulli

Summary: Bone metastasis is a significant problem in breast, prostate, and other major cancers, causing high mortality and decreased quality of life. Immunotherapies have not been approved for treating bone metastasis, and the current approved immunotherapies show limited effectiveness. Understanding the tumor microenvironment in bone metastasis is crucial for developing novel therapies. The concept of osteoimmuno-oncology (OIO) emphasizes the interactions between tumor, immune, and bone cells, providing potential targets for bone metastasis. This review identifies 24 immunotherapies in preclinical or clinical development with evaluation in bone metastasis, offering insights into immuno-oncology drug development in the context of bone metastasis.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Dermatology

Melanoma brain metastases: Biological basis and novel therapeutic strategies

Manali Phadke, Alpaslan Ozgun, Zeynep Eroglu, Keiran S. M. Smalley

Summary: The development of brain metastases is the deadliest complication of advanced melanoma, and recent progress has been made in therapies for melanoma brain metastases (MBM). However, there are lower response durations for intracranial metastases compared to extracranial metastases, possibly due to unique features of the brain microenvironment. Current research focuses on the biology and pathophysiology of melanoma brain metastasis development, as well as the challenges faced in clinical trials and treatment for MBM patients.

EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Review Cell Biology

Emerging Roles of Long Noncoding RNAs in Immuno-Oncology

Xin Wang, Xu Wang, Midie Xu, Weiqi Sheng

Summary: Long noncoding RNAs (lncRNAs) play a crucial role in cancer development by impacting the tumor microenvironment through chromatin remodeling, transcriptional and post-transcriptional regulation. Additionally, the function of lncRNAs in immune recognition and evasion in tumor-infiltrating immune cells has raised significant interest in immuno-oncology.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma

Verdiana Trappetti, Jennifer M. Fazzari, Cristian Fernandez-Palomo, Maximilian Scheidegger, Vladislav Volarevic, Olga A. Martin, Valentin G. Djonov

Summary: Melanoma is a highly invasive and challenging type of skin cancer. Conventional therapies like wide excision and radiotherapy have limitations due to the inherent radioresistance of melanoma. A novel technique called Microbeam Radiation Therapy (MRT) has shown promise in overcoming these limitations by increasing dose delivery, potentially leading to complete tumor ablation or improved tumor control.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

Lights and Shadows in Immuno-Oncology Drug Development

Milana Bergamino Sirven, Sonia Pernas, Maggie C. U. Cheang

Summary: The introduction of immunotherapy has revolutionized cancer treatment, but brings opportunities and challenges. For successful development of promising IO drugs, key areas such as trial designs, surrogate endpoints, biomarkers, toxicity monitoring, and collaborative approaches need to be redefined. These aspects are crucial for optimizing outcomes and accelerating approvals in immuno-oncology.

CANCERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

Alice Indini, Fausto Roila, Francesco Grossi, Daniela Massi, Mario Mandala

Summary: Mucosal melanoma is a rare and aggressive subtype of melanoma that has shown poor response to novel treatment approaches. Recent molecular studies have revealed potential therapeutic targets and the potential benefits of immunotherapy in this disease. However, further research is needed to confirm these findings in different studies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Agriculture, Dairy & Animal Science

From Keratoma to Anaplastic Malignant Melanoma in a Horse's Hoof

Elzbieta Stefanik, Kamil Gorski, Bernard Turek, Olga Drewnowska-Szczepakowska, Katarzyna Kliczkowska-Klarowicz, Aleksandra Stefanik

Summary: This article describes a case report of a hoof lesion initially diagnosed as a keratoma, but evolved into an anaplastic malignant melanoma over time. Melanomas in horses are typically associated with older, gray horses, but they can rarely affect non-gray horses.

ANIMALS (2022)

添加到收藏夹

Review Immunology

The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies

Weiyuan Wang, Melanie Cristina Lopez McDonald, Christine Kim, Mirielle Ma, Zetao (Tommy) Pan, Charlotte Kaufmann, David A. Frank

Summary: STATs are a family of transcription factors involved in various cellular processes. Dysregulation of STATs in tumors directly contributes to cancer pathogenesis. STAT1 suppresses tumor formation while STAT3 promotes tumor development. This review investigates the specific roles of STAT1 and STAT3 in both normal physiology and cancer biology, explores their interactions, and provides insights into therapeutic strategies by modulating their transcriptional activity.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Biotechnology & Applied Microbiology

New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma

Alexander Z. Wei, Ashray B. Maniar, Richard D. Carvajal

Summary: Uveal melanoma (UM) is a rare ocular malignancy with limited treatment options for metastatic disease. Efforts are being made to understand the disease-specific mechanisms and identify potential targets for therapy. Preclinical studies and clinical trials are being conducted to develop targeted therapies for UM.

CANCER GENE THERAPY (2022)

添加到收藏夹

Article Oncology

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

Simone M. Goldinger, Kristina Buder-Bakhaya, Serigne N. Lo, Andrea Forschner, Meredith McKean, Lisa Zimmer, Chloe Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth I. Buchbinder, Paolo A. Ascierto, Ralf Gutzmer, Elisa A. Rozeman, Christoph Hoeller, Douglas B. Johnson, Anja Gesierich, Peter Koelblinger, Naima Bennannoune, Justine Cohen, Katharina C. Kaehler, Melissa A. Wilson, Jonathan Cebon, Victoria Atkinson, Jessica L. Smith, Olivier Michielin, Georgina Long, Jessica C. Hassel, Benjamin Weide, Lauren E. Haydu, Dirk Schadendorf, Grant McArthur, Patrick A. Ott, Christian Blank, Caroline Robert, Ryan Sullivan, Axel Hauschild, Matteo S. Carlino, Claus Garbe, Michael A. Davies, Alexander M. Menzies

Summary: Chemotherapy has limited activity in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although the activity varies among different chemotherapy regimens.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Correction Oncology

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) (vol 152, pg 116, 2021)

Helen Gogas, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Naoya Yamazaki, Carmen Loquai, Paola Queirolo, Groot J. de Willem, Abir T. Sellier, Jeanne Suissa, Juliette Murris, Ashwin Gollerkeri, Caroline Robert, Keith T. Flaherty

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsova, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo A. Ascierto

Summary: In patients with BRAF V600-mutant melanoma, the combination treatment of encorafenib plus binimetinib showed continued long-term benefits and a consistent safety profile over 5 years.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial COMBI-i)

Hussein A. Tawbi, Caroline Robert, Jan C. Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Gullu Gorgun, Keith T. Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina Long, Paul D. Nathan, Paolo A. Ascierto

Summary: This study provides important information on drug treatment for melanoma, particularly for potential target subgroups with spartalizumab plus dabrafenib and trametinib therapy. These results have significant implications for future clinical decision-making and personalized treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle

Sami Antoun, Emilie Lanoy, Samy Ammari, Siham Farhane, Lisa Martin, Caroline Robert, David Planchard, Emilie Routier, Anne Laure Voisin, Sabine Messayke, Stephane Champiat, Jean Marie Michot, Salim Laghouati, Olivier Lambotte, Aurelien Marabelle, Vickie Baracos

Summary: The association between high body mass index (BMI) and longer survival in patients on immune checkpoint inhibitors (ICIs) is inconsistent. This study found that the 'obesity paradox' disappeared when accounting for confounders such as cancer type and manifestations of depletion. Weight loss and reduced skeletal muscle mass were observed in patients across all BMI categories, and weight loss was associated with shorter survival in both melanoma and non-small cell lung cancer (NSCLC) patients.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors

Franck Carbonnel, Emilie Routier, Thierry Lazure, Charlotte Mussini, Christophe Bellanger, Carine Merklen, Bakhtiar Bejou, Anthony Buisson, Aurelien Amiot, Antoine Meyer, Catherine Dong, Caroline Robert

Summary: This study provides the first systematic description of colitis caused by dual blockade of BRAF and MEK kinases in the treatment of melanoma. The study found that severe colitis characterized by ulcerations of the right colon can occur, leading to symptoms such as diarrhea, rectal bleeding, abdominal pain, and intestinal obstruction. In some cases, the colitis was associated with ischemic changes and inflammation.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Oncology

Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1

Caroline Robert, Celeste Lebbe, Thierry Lesimple, Eija Lundstrom, Valerie Nicolas, Bruno Gavillet, Philippa Crompton, Barouyr Baroudjian, Emilie Routier, Ferdy J. Lejeune

Summary: This study evaluated the safety and efficacy of combined treatment with GnRH agonist triptorelin and nivolumab in male melanoma patients resistant to anti-PD-1. The results showed that this combination therapy effectively controlled the disease, with a disease control rate of 42.8% according to RECIST criteria. However, evidence for thymus rejuvenation was limited.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Post-transcriptional polyadenylation site cleavage maintains 3' -end processing upon DNA damage

Rym Sfaxi, Biswendu Biswas, Galina Boldina, Mandy Cadix, Nicolas Servant, Huimin Chen, Daniel R. Larson, Martin Dutertre, Caroline Robert, Stephan Vagner

Summary: The recognition of polyadenylation signals (PAS) in eukaryotic pre-mRNAs is usually coupled to transcription termination, occurring while pre-mRNA is chromatin-bound. However, for some pre-mRNAs, this 3'-end processing occurs post-transcriptionally, i.e., through a co-transcriptional cleavage (CoTC) event downstream of the PAS, leading to chromatin release and subsequent PAS cleavage in the nucleoplasm. These findings indicate that CoTC-type cleavage of pre-mRNAs, followed by PAS cleavage in the nucleoplasm, allows certain pre-mRNAs to escape 3'-end processing inhibition in response to UV-induced DNA damage.

EMBO JOURNAL (2023)

添加到收藏夹

Letter Oncology

Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist

Marie Boileau, Emilie Routier, Arnaud Pouvelle, Olivier Lambotte, Caroline Robert

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long

Summary: This study investigates the efficacy of a combination therapy strategy involving low-dose ipilimumab (IPI) and an anti-PD1 antibody in advanced melanoma. The results show that the majority of patients who progress following low-dose IPI and subsequently receive IPI 3 mg/kg (IPI3) have a positive response to this treatment. This suggests that the dosage of IPI is critical for certain patients.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Letter Oncology

eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma

Antoine Moya-Plana, Carine Ngo, Emilie Lanoy, Stephan Vagner, Caroline Robert

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

Caroline Robert, Matteo S. Carlino, Catriona Mcneil, Antoni Ribas, Jean-Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil I. Daud, Omid Hamid, James Larkin, James Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long

Summary: Clinical trials often have multiple end points that mature at different times. Clinical Trial Updates provide a platform to publish additional results from studies where the primary end point has already been reported. This article presents the 7-year follow-up and efficacy results of pembrolizumab in advanced melanoma patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma

Celine Boutros, Djaouida Belkadi-Sadou, Antoine Marchand, Severine Roy, Emilie Routier, Caroline Robert

Summary: Immune checkpoint inhibitors (ICIs) have shown robust antitumor activity and tolerable safety in advanced melanoma. Long-term outcomes of patients who benefitted from this therapy and remain progression-free despite ICI discontinuation are now available. This review discusses the characteristics of long-term responders to ICIs and addresses the question of cure.

CURRENT ONCOLOGY REPORTS (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients

Andrey A. Yurchenko, Fatemeh Rajabi, Tirzah Braz-Petta, Hiva Fassihi, Alan Lehmann, Chikako Nishigori, Jinxin Wang, Ismael Padioleau, Konstantin Gunbin, Leonardo Panunzi, Fanny Morice-Picard, Pierre Laplante, Caroline Robert, Patricia L. Kannouche, Carlos F. M. Menck, Alain Sarasin, Sergey I. Nikolaev

Summary: Xeroderma pigmentosum (XP) is a rare genetic disorder associated with an increased risk of skin cancer. In this study, the authors analyze skin cancer genomes from five different XP groups, revealing genetic and molecular factors related to the mutational profile and UV-induced mutagenesis in XP.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Oncology

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Yi Pu, Lu Li, Haoning Peng, Lunxu Liu, Dominique Heymann, Caroline Robert, Francois Vallette, Shensi Shen

Summary: Drug-tolerant persister (DTP) cell populations have been discovered in antibiotic-resistant bacterial biofilms and have also been identified in cancer cells. They are linked with treatment resistance and targeting these cells may offer new treatment opportunities.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.